<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40071757</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associated With Response in Locally Advanced Rectal Cancer.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>725</EndPage><MedlinePgn>713-725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003660</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The extent of neoadjuvant therapy response, before surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored. Within operable colorectal cancer, circulating markers of elevated systemic inflammation are associated with poor survival. Studies have suggested that elevated pre-neoadjuvant inflammatory markers, including the modified Glasgow prognostic score and the neutrophil:lymphocyte ratio, are associated with a poorer response.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to comprehensively evaluate hematological markers of inflammation before and after neoadjuvant therapy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Single health board from a prospectively maintained regional cancer database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive patients with locally advanced rectal cancer who underwent curative-intent neoadjuvant therapy between June 2016 and July 2021.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Elevated markers of the systemic inflammatory response before and after neoadjuvant therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 278 patients (67.3% men, median age 65 years) were identified. A complete response (clinical or pathological complete response) was achieved in 27.34%, and good tumor regression was achieved in 37.05% (tumor regression grading 0-1). No pre-neoadjuvant marker was found to be associated with response or regression. Multivariate analysis of post-neoadjuvant variables revealed an elevated modified Glasgow prognostic score (OR 2.8; 95% CI, 1.22-6.41; p = 0.015), and an elevated CEA (OR 4.09; 95% CI, 1.6-10.44; p = 0.003) was found to be independently associated with incomplete response. An elevated post-neoadjuvant modified Glasgow prognostic score (OR 2.14; 95% CI, 1.08-4.23; p = 0.029) was also independently associated with poor tumor regression on multivariate analysis.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design and slight variation in the timing of post-neoadjuvant blood tests were limitations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report that post-neoadjuvant modified Glasgow prognostic score is associated with poorer response and regression, potentially indicating that radiation resistance is associated with the development of a protumor inflammatory environment. Further work is required to define the local intratumoral processes associated with response and their interrelationship with systemic parameters. Ultimately, there may be a rationale for testing anti-inflammatory strategies in combination with radiotherapy as an option for optimizing treatment response. See Video Abstract .</AbstractText><AbstractText Label="LOS MARCADORES CIRCULANTES DE INFLAMACIN SISTMICA, MEDIDOS DESPUS DE COMPLETAR LA TERAPIA NEOADYUVANTE, SE ASOCIAN CON LA RESPUESTA EN EL CNCER RECTAL LOCALMENTE AVANZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:El grado de respuesta a la terapia neoadyuvante, antes de la cirug&#xed;a, es un pronosticador importante en el c&#xe1;ncer rectal localmente avanzado. Existe un espectro de respuestas, con una escasez de medidas confiables. La respuesta del hu&#xe9;sped al tratamiento permanece inexplorada. Dentro del c&#xe1;ncer colorrectal operable, los marcadores circulantes de inflamaci&#xf3;n sist&#xe9;mica elevada se asocian con una supervivencia deficiente. Los estudios han sugerido que los marcadores inflamatorios pre-neoadyuvantes elevados, incluidos; el puntaje pron&#xf3;stico de Glasgow modificado y la proporci&#xf3;n neutr&#xf3;filos::linfocitos, se asocian con una respuesta peor.OBJETIVO:Este estudio tuvo como objetivo evaluar de manera integral los marcadores hematol&#xf3;gicos de inflamaci&#xf3;n antes y despu&#xe9;s de la terapia neoadyuvante.DISE&#xd1;O:Estudio de cohorte longitudinal.ESCENARIO:Junta de salud &#xfa;nica de una base de datos de c&#xe1;ncer regional mantenida prospectivamente.PACIENTES:Pacientes consecutivos con c&#xe1;ncer rectal localmente avanzado que se sometieron a terapia neoadyuvante con intenci&#xf3;n curativa entre; Junio de 2016-julio de 2021.PRINCIPALES MEDIDAS DE RESULTADOS:Marcadores elevados de la respuesta inflamatoria sist&#xe9;mica antes y despu&#xe9;s de la terapia neoadyuvante.RESULTADOS:278 pacientes. 67,3 % varones, mediana de edad 65. El 27,34 % logr&#xf3; una "respuesta completa" (respuesta completa cl&#xed;nica o patol&#xf3;gica). El 37,05 % logr&#xf3; una "buena regresi&#xf3;n tumoral" (clasificaci&#xf3;n de regresi&#xf3;n tumoral de 0 a 1). Ning&#xfa;n marcador pre-neoadyuvante se asoci&#xf3; con la respuesta o la regresi&#xf3;n. El an&#xe1;lisis multivariado de las variables pos-neoadyuvantes revel&#xf3; un puntaje pron&#xf3;stico de Glasgow modificado elevado (OR 2,8; IC del 95 % 1,22-6,41; p = 0,015) y un ant&#xed;geno carcinoembrionario elevado (OR 4,09; IC del 95 % 1,6-10,44; p = 0,003) asociados de forma independiente con una respuesta incompleta. Un puntaje pron&#xf3;stico de Glasgow modificado post-neoadyuvante elevado (OR 2,14, IC del 95 % 1,08-4,23, p = 0,029) tambi&#xe9;n se asoci&#xf3; de forma independiente con una regresi&#xf3;n tumoral deficiente en el an&#xe1;lisis multivariable.LIMITACIONES:Dise&#xf1;o retrospectivo. Ligera variaci&#xf3;n en el momento de los an&#xe1;lisis de sangre pos-neoadyuvante.CONCLUSIONES:Informamos que el puntaje pron&#xf3;stico de Glasgow modificado pos-neoadyuvante se asoci&#xf3; con una respuesta y regresi&#xf3;n m&#xe1;s deficientes, lo que podr&#xed;a indicar que la resistencia a la radiaci&#xf3;n est&#xe1; asociada con el desarrollo de un entorno inflamatorio protumoral. Se requieren m&#xe1;s estudios para definir los procesos intratumorales locales asociados con la respuesta y su interrelaci&#xf3;n con los par&#xe1;metros sist&#xe9;micos. En &#xfa;ltima instancia, puede haber una justificaci&#xf3;n para probar estrategias antiinflamatorias en combinaci&#xf3;n con radioterapia como una opci&#xf3;n para optimizar la respuesta al tratamiento. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Ross K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Cathail</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Garscube Estate, Bearsden, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Harikrishnan S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Jonathan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Radiology/Imaging Department, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Donald C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horgan</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roxburgh</LastName><ForeName>Campbell S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical complete response</Keyword><Keyword MajorTopicYN="N">Locally advanced rectal cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant</Keyword><Keyword MajorTopicYN="N">Organ preservation</Keyword><Keyword MajorTopicYN="N">Pathological complete response</Keyword><Keyword MajorTopicYN="N">Rectal cancer</Keyword><Keyword MajorTopicYN="N">Systemic inflammatory response</Keyword><Keyword MajorTopicYN="N">Tumor regression</Keyword><Keyword MajorTopicYN="N">modified Glasgow prognostic score</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40071757</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003660</ArticleId><ArticleId IdType="pii">00003453-202506000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22&#x2013;iv40.</Citation></Reference><Reference><Citation>Fokas E, Str&#xf6;bel P, Fietkau R, et al.; German Rectal Cancer Study Group. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst. 2017;109. doi:10.1093/jnci/djx095.</Citation></Reference><Reference><Citation>Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918&#x2013;928.</Citation></Reference><Reference><Citation>Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2030097.</Citation></Reference><Reference><Citation>Sell NM, Qwaider YZ, Goldstone RN, et al. Ten-year survival after pathologic complete response in rectal adenocarcinoma. J Surg Oncol. 2021;123:293&#x2013;298.</Citation></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation></Reference><Reference><Citation>Kong JC, Guerra GR, Warrier SK, et al. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2018;20:574&#x2013;585.</Citation></Reference><Reference><Citation>Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926&#x2013;1933.</Citation></Reference><Reference><Citation>Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.</Citation></Reference><Reference><Citation>Loughrey MB, Webster F, Arends MJ, et al. Dataset for pathology reporting of colorectal cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Ann Surg. 2022;275:e549&#x2013;e561.</Citation></Reference><Reference><Citation>Dreyer SB, Powell AG, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann Surg Oncol. 2017;24:1295&#x2013;1303.</Citation></Reference><Reference><Citation>Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori. 2019;105:434&#x2013;440.</Citation></Reference><Reference><Citation>Bong JW, Lim SB, Ryu H, et al. Effect of anaemia on the response to preoperative chemoradiotherapy for rectal cancer. ANZ J Surg. 2021;91:E286&#x2013;E291.</Citation></Reference><Reference><Citation>Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol. 2020;26:7022&#x2013;7035.</Citation></Reference><Reference><Citation>Machado Carvalho JV, Dutoit V, Corr&#xf2; C, Koessler T. Promises and challenges of predictive blood biomarkers for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cells. 2023;12:413.</Citation></Reference><Reference><Citation>Lai S, Huang L, Luo S, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett. 2020;20:2763&#x2013;2770.</Citation></Reference><Reference><Citation>Wu Z, Zhang J, Cai Y, et al. Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. Medicine (Baltim). 2018;97:e11435.</Citation></Reference><Reference><Citation>Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249:788&#x2013;793.</Citation></Reference><Reference><Citation>McMahon R, O&#x2019;Cathail SM, Steele C, Platt J, Horgan P, Roxburgh CS. Circulating markers of systemic inflammation, measured after completion of neoadjuvant therapy, independently predict response in locally advanced rectal cancer [ASCRS abstract T101]. Dis Colon Rectum. 2024;67:e499&#x2013;e500.</Citation></Reference><Reference><Citation>He L, Li H, Cai J, et al. Prognostic value of the Glasgow prognostic score or modified Glasgow prognostic score for patients with colorectal cancer receiving various treatments: a systematic review and meta-analysis. Cell Physiol Biochem. 2018;51:1237&#x2013;1249.</Citation></Reference><Reference><Citation>Xu N, Li W, Huang F, et al. Systemic inflammation-based predictors of pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. J Cancer Res Ther. 2022;18:438&#x2013;444.</Citation></Reference><Reference><Citation>Jeon BH, Shin US, Moon SM, et al. Neutrophil to lymphocyte ratio: a predictive marker for treatment outcomes in patients with rectal cancer who underwent neoadjuvant chemoradiation followed by surgery. Ann Coloproctol. 2019;35:100&#x2013;106.</Citation></Reference><Reference><Citation>Li A, He K, Guo D, et al. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer. Future Oncol. 2019;15:3233&#x2013;3242.</Citation></Reference><Reference><Citation>Lee H, Park HC, Park W, et al. Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer. Radiat Oncol J. 2012;30:117&#x2013;123.</Citation></Reference><Reference><Citation>Gray S, Axelsson B. The prevalence of deranged C-reactive protein and albumin in patients with incurable cancer approaching death. PLoS One. 2018;13:e0193693.</Citation></Reference><Reference><Citation>Arends J, Strasser F, Gonella S, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open. 2021;6:100092.</Citation></Reference><Reference><Citation>Swanton C, Bernard E, Abbosh C, et al. Embracing cancer complexity: Hallmarks of systemic disease. Cell. 2024;187:1589&#x2013;1616.</Citation></Reference><Reference><Citation>Saal J, Bald T, Eckstein M, et al. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer. 2024;189:107505.</Citation></Reference><Reference><Citation>Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.</Citation></Reference><Reference><Citation>Partl R, Lukasiak K, Thurner EM, Renner W, Stranzl-Lawatsch H, Langsenlehner T. The elevated pre-treatment C-reactive protein predicts poor prognosis in patients with locally advanced rectal cancer treated with neo-adjuvant radiochemotherapy. Diagnostics (Basel). 2020;10:780.</Citation></Reference><Reference><Citation>Li M, Xiao Q, Venkatachalam N, et al. Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. Ther Adv Med Oncol. 2022;14:17588359221077972.</Citation></Reference><Reference><Citation>Chandramohan A, Mittal R, Dsouza R, et al. Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis. 2022;24:428&#x2013;438.</Citation></Reference><Reference><Citation>Hanna CR, O&#x2019;Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol. 2021;16:163.</Citation></Reference><Reference><Citation>Groarke JD, Crawford J, Collins SM, et al. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024;391:2291&#x2013;2303.</Citation></Reference><Reference><Citation>Shi X, Zhao M, Shi B, et al. Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front Oncol. 2022;12:916840.</Citation></Reference><Reference><Citation>Eastern Rectal Cancer Response Collaborative, Ireland. A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2022;37:957&#x2013;965.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34351884</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1665-1146</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Boletin medico del Hospital Infantil de Mexico</Title><ISOAbbreviation>Bol Med Hosp Infant Mex</ISOAbbreviation></Journal><ArticleTitle>Effects of hospitalization on children's sleep pattern irrespective of sleep problems history.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>286</EndPage><MedlinePgn>279-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/BMHIM.20000277</ELocationID><Abstract><AbstractText Label="INTRODUCCI&#xd3;N">El sue&#xf1;o es un proceso neurofisiol&#xf3;gico necesario para el desarrollo cerebral cuyos patrones var&#xed;an con la edad. El objetivo de este estudio fue comparar el comportamiento del patr&#xf3;n del sue&#xf1;o en ni&#xf1;os con y sin problemas previos del sue&#xf1;o (PPS) durante las primeras 48 horas de hospitalizaci&#xf3;n, y analizar los factores influyentes en la interrupci&#xf3;n del sue&#xf1;o.</AbstractText><AbstractText Label="M&#xc9;TODOS">Se realiz&#xf3; un estudio de cohorte prospectivo. Con el consentimiento informado, se siguieron dos grupos de pacientes &lt; 17 a&#xf1;os ingresados al &#xe1;rea de hospitalizaci&#xf3;n por diversas enfermedades agudas. El antecedente de PPS se determin&#xf3; con el Cuestionario breve del sue&#xf1;o. El patr&#xf3;n del sue&#xf1;o se observ&#xf3; por 48 horas y se registraron las horas totales de sue&#xf1;o diario, los minutos para conciliar el sue&#xf1;o nocturno, los minutos de despertares nocturnos y las siestas diurnas. Se registraron las acciones m&#xe9;dicas asociadas con el tiempo de sue&#xf1;o.</AbstractText><AbstractText Label="RESULTADOS">En promedio, la duraci&#xf3;n total de las horas de sue&#xf1;o por d&#xed;a aument&#xf3; una hora en los pacientes con PPS, mejorando la higiene de sue&#xf1;o en este grupo. En el grupo de ni&#xf1;os sin PPS se observ&#xf3; una disminuci&#xf3;n transitoria de las horas totales de sue&#xf1;o y un incremento en el tiempo para dormirse, los minutos de siestas diurnas y las vigilias nocturnas. El sonido de las alarmas, la colocaci&#xf3;n de venoclisis y de sondas de drenaje, as&#xed; como la entrada y salida del personal de salud a las habitaciones, fueron identificados como factores de interrupci&#xf3;n del sue&#xf1;o.</AbstractText><AbstractText Label="CONCLUSIONES">La hospitalizaci&#xf3;n altera los patrones del sue&#xf1;o, sobre todo en ni&#xf1;os sin problemas previos del sue&#xf1;o. Se recomienda explorar los patrones del sue&#xf1;o en los ni&#xf1;os hospitalizados y reducir, en lo posible, los factores externos asociados a su perturbaci&#xf3;n.</AbstractText><AbstractText Label="BACKGROUND">Sleep is a neurophysiologic process necessary for brain development. However, sleep patterns change with aging. This study aimed to compare the sleep pattern in pediatric patients with and with no previous sleep problems (PSP) during the first 48 hours of hospitalization and analyze the factors influencing sleep disruption.</AbstractText><AbstractText Label="METHODS">We conducted a prospective cohort study. Under informed consent, two groups of patients &lt; 17 years admitted to a hospital for acute illnesses were followed. The history of PSP was determined with the Brief sleep questionnaire. For 48 hours, the sleep pattern was observed in terms of total hours of daily sleep, daytime naps, night awakenings, and time to fall asleep. We recorded actions of attention associated with sleep time.</AbstractText><AbstractText Label="RESULTS">Patients with PSP showed an increased total duration of sleep hours per day by an average of one hour, improving the sleep pattern. In patients with no PSP, the total hours of sleep diminished transitorily and the time elapsed to initiate sleep, the number of daytime naps, and night awakenings increased. Alarms sound, the presence of vein catheters and tubes, and the entry and exit of healthcare personnel to the rooms were identified as critical factors of sleep interruptions.</AbstractText><AbstractText Label="CONCLUSIONS">Hospitalization alters sleep patterns, especially in children without previous sleep problems. We recommend exploring sleep patterns in all hospitalized children and reducing external factors associated with their disturbance as much as possible.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Far&#xed;as-Fern&#xe1;ndez</LastName><ForeName>Maite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Facultad Mexicana de Medicina, Universidad La Salle M&#xe9;xico. Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rend&#xf3;n-Mac&#xed;as</LastName><ForeName>Mario E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Escuela de Medicina, Universidad Panamericana. Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias-Leboreiro</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico. Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bern&#xe1;rdez-Zapata</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico. Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordillo-Rodr&#xed;guez</LastName><ForeName>Lucina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Facultad Mexicana de Medicina, Universidad La Salle M&#xe9;xico. Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Efectos de la hospitalizaci&#xf3;n en el patr&#xf3;n del sue&#xf1;o en ni&#xf1;os independientemente de antecedentes de problemas del sue&#xf1;o.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Bol Med Hosp Infant Mex</MedlineTA><NlmUniqueID>0414106</NlmUniqueID><ISSNLinking>0539-6115</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="Y">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hospitalizaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Sleep</Keyword><Keyword MajorTopicYN="N">Sleep disorders</Keyword><Keyword MajorTopicYN="N">Sue&#xf1;o</Keyword><Keyword MajorTopicYN="N">Trastornos del sue&#xf1;o</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34351884</ArticleId><ArticleId IdType="doi">10.24875/BMHIM.20000277</ArticleId><ArticleId IdType="pii">j78/4/279</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34016825</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Treatment of Complex Idiopathic Fistula-in-Ano Using Autologous Centrifuged Adipose Tissue Containing Progenitor Cells: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1276</StartPage><EndPage>1285</EndPage><MedlinePgn>1276-1285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001924</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mesenchymal stem cells derived from adipose tissue have been successfully used to promote sphincter-saving anal fistula healing.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to evaluate the efficacy and safety of the use of autologous centrifuged adipose tissue in the healing process of cryptoglandular complex anal fistulas.</AbstractText><AbstractText Label="DESIGN">This is a randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a single center.</AbstractText><AbstractText Label="PATIENTS">Patients with complex perianal fistulas not associated with Crohn's disease were included. Rectovaginal fistulas were not included.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomly allocated to receive treatment with centrifuged adipose tissue injection (experimental group) and without injection (control group) in combination with fistula surgery.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was defined as the proportion of patients with complete fistula closure at 4 weeks (short-term outcome) and 6 months after surgery (long-term outcome). Healing was defined as when the external opening was closed with no perianal discharge on clinical assessment. The secondary outcome was safety that was evaluated by the analysis of adverse events up to 3 months after surgery. Pelvic MRI was performed at 3 months to assure safety and the accuracy of the clinical determination of healing. Postoperative pain, return to work/daily activities, persistent closure at 6 months, fecal incontinence, and patient satisfaction were evaluated.</AbstractText><AbstractText Label="RESULTS">Fifty-eight patients who received centrifuged adipose tissue injection and 58 patients who did not receive centrifuged adipose tissue injection were included in the safety and efficacy analysis. After 4 weeks, the healing rate was 63.8% in the experimental group compared with 15.5% in the control group (p &lt; 0.001). No major adverse events were recorded. Postoperative anal pain was significantly lower in the injection group. Time taken to return to work/daily activities was significantly shorter in the experimental group (3 days) than in the control group (17 days). At 6 months, persistent closure was similar in the 2 groups (86.2% vs 81%). Fecal Incontinence Score at 6 months after surgery was identical to the preoperative score. Patient satisfaction was high in both groups.</AbstractText><AbstractText Label="LIMITATIONS">The absence of blinding, the lack of correlation between stem cell content, and the clinical outcome were limitations of the study.</AbstractText><AbstractText Label="CONCLUSIONS">Autologous centrifuged adipose tissue injection may represent a safe, efficacious, and inexpensive option for the treatment of complex fistula-in-ano. See Video Abstract at http://links.lww.com/DCR/B607.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION">URL: https://www.clinicaltrials.gov. Identifier: NCT04326907.</AbstractText><AbstractText Label="EFICACIA Y SEGURIDAD DEL TRATAMIENTO DE LA FSTULA ANAL COMPLEJA IDIOPTICA UTILIZANDO TEJIDO ADIPOSO CENTRIFUGADO AUTLOGO QUE CONTIENE CLULAS PROGENITORAS UN ENSAYO CONTROLADO ALEATORIO">ANTECEDENTES:Las c&#xe9;lulas madre mesenquimales derivadas del tejido adiposo se han utilizado con &#xe9;xito para promover la curaci&#xf3;n de la f&#xed;stula anal con preservaci&#xf3;n de esf&#xed;nter.OBJETIVO:El objetivo de este estudio fue evaluar la eficacia y seguridad del uso de tejido adiposo aut&#xf3;logo centrifugado en el proceso de cicatrizaci&#xf3;n de f&#xed;stulas anales complejas de origen criptoglandular.DISE&#xd1;O:Ensayo controlado aleatorio.ENTORNO CL&#xcd;NICO:Estudio unic&#xe9;ntrico.PACIENTES:Se incluyeron pacientes con f&#xed;stulas perianales complejas no asociadas a Enfermedad de Crohn. No se incluyeron las f&#xed;stulas rectovaginales.INTERVENCIONES:Los pacientes fueron asignados aleatoriamente para recibir tratamiento con inyecci&#xf3;n de tejido adiposo centrifugado (grupo experimental) y sin inyecci&#xf3;n (grupo de control) en combinaci&#xf3;n con cirug&#xed;a de f&#xed;stula.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:El resultado primario se defini&#xf3; como la proporci&#xf3;n de pacientes con cierre completo de la f&#xed;stula a las 4 semanas (resultado a corto plazo) y 6 meses despu&#xe9;s de la cirug&#xed;a (resultado a largo plazo). La curaci&#xf3;n se defini&#xf3; cuando orificio externo se cerr&#xf3; sin secreci&#xf3;n perianal en la valoraci&#xf3;n cl&#xed;nica. El resultado secundario fue la seguridad que se evalu&#xf3; mediante el an&#xe1;lisis de los eventos adversos (EA) hasta 3 meses despu&#xe9;s de la cirug&#xed;a. La resonancia magn&#xe9;tica p&#xe9;lvica se realiz&#xf3; a los 3 meses para garantizar la seguridad y la precisi&#xf3;n cl&#xed;nica de la curaci&#xf3;n. Se evalu&#xf3; el dolor postoperatorio, el regreso al trabajo / actividades diarias, el cierre persistente a los 6 meses, la incontinencia fecal y la satisfacci&#xf3;n del paciente.RESULTADOS:Cincuenta y ocho pacientes que recibieron inyecci&#xf3;n de tejido adiposo centrifugado y 58 pacientes que no recibieron inyecci&#xf3;n de tejido adiposo centrifugado se incluyeron en el an&#xe1;lisis de seguridad y eficacia. Despu&#xe9;s de 4 semanas, la tasa de curaci&#xf3;n fue del 63,8% en el grupo experimental en comparaci&#xf3;n con el 15,5% en el grupo de control (p &lt;0,001). No se registraron eventos adversos importantes. El dolor anal posoperatorio fue significativamente menor en el grupo de inyecci&#xf3;n. El tiempo necesario para volver al trabajo / actividades diarias fue significativamente menor en el grupo experimental (3 d&#xed;as) con respecto al grupo de control (17 d&#xed;as). A los 6 meses, el cierre persistente fue similar en los dos grupos (86,2% vs 81%). La puntuaci&#xf3;n de incontinencia fecal a los 6 meses despu&#xe9;s de la cirug&#xed;a fue id&#xe9;ntica a la puntuaci&#xf3;n preoperatoria. La satisfacci&#xf3;n del paciente fue muy alta en ambos grupos.LIMITACIONES:Ausencia de cegamiento, falta de correlaci&#xf3;n entre el contenido de c&#xe9;lulas madre y el resultado cl&#xed;nico.CONCLUSIONES:La inyecci&#xf3;n de tejido adiposo centrifugado aut&#xf3;logo puede representar una opci&#xf3;n segura, eficaz y econ&#xf3;mica para el tratamiento de la f&#xed;stula anal compleja.Registro de ensayos cl&#xed;nicos: www.clinicaltrials.gov, identificador NCT04326907; No patrocinado.Consulte Video Resumen en http://links.lww.com/DCR/B607.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ascanelli</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamboni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section of Translational of Medicine and Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campioni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Provincial Unique Laboratory Department, University Hospital Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grazia Sibilla</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chimisso</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zollino</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section of Translational of Medicine and Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valpiani</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Innovation Quality and Accreditation Unit, S. Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcoforo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04326907</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005242" MajorTopicYN="N">Fecal Incontinence</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="N">Rectal Fistula</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062707" MajorTopicYN="N">Return to Work</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34016825</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001924</ArticleId><ArticleId IdType="pii">00003453-202110000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Limura E, Giordano P. Modern management of anal fistula. World J Gastroenterol. 2015;21:12&#x2013;20.</Citation></Reference><Reference><Citation>van Onkelen RS, Gosselink MP, Schouten WR. Is it possible to improve the outcome of transanal advancement flap repair for high transsphincteric fistulas by additional ligation of the intersphincteric fistula tract? Dis Colon Rectum. 2012;55:163&#x2013;166.</Citation></Reference><Reference><Citation>Dudukgian H, Abcarian H. Why do we have so much trouble treating anal fistula? World J Gastroenterol. 2011;17:3292&#x2013;3296.</Citation></Reference><Reference><Citation>Gimble JM, Guilak F, Bunnell BA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther. 2010;1:19.</Citation></Reference><Reference><Citation>Garc&#xed;a-Olmo D, Garc&#xed;a-Arranz M, Herreros D, Pascual I, Peiro C, Rodr&#xed;guez-Montes JA. A phase I clinical trial of the treatment of Crohn&#x2019;s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416&#x2013;1423.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79&#x2013;86.</Citation></Reference><Reference><Citation>Aust L, Devlin B, Foster SJ, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. 2004;6:7&#x2013;14.</Citation></Reference><Reference><Citation>Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279&#x2013;4295.</Citation></Reference><Reference><Citation>Gimble JM, Bunnell BA, Guilak F. Human adipose-derived cells: an update on the transition to clinical translation. Regen Med. 2012;7:225&#x2013;235.</Citation></Reference><Reference><Citation>Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012;27:595&#x2013;600.</Citation></Reference><Reference><Citation>Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn&#x2019;s fistula. Stem Cells. 2013;31:2575&#x2013;2581.</Citation></Reference><Reference><Citation>Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn&#x2019;s fistula: a phase I clinical study. Cell Transplant. 2013;22:279&#x2013;285.</Citation></Reference><Reference><Citation>Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55:762&#x2013;772.</Citation></Reference><Reference><Citation>Choi S, Ryoo SB, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn&#x2019;s disease: a phase II clinical trial for safety and efficacy. Tech Coloproctol. 2017;21:345&#x2013;353.</Citation></Reference><Reference><Citation>Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2017;153:59&#x2013;62.e2.</Citation></Reference><Reference><Citation>Park KJ, Ryoo SB, Kim JS, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn&#x2019;s disease: a pilot clinical trial. Colorectal Dis. 2016;18:468&#x2013;476.</Citation></Reference><Reference><Citation>de la Portilla F, Alba F, Garc&#xed;a-Olmo D, Herrer&#xed;as JM, Gonz&#xe1;lez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn&#x2019;s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313&#x2013;323.</Citation></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Naldini G, Sturiale A, Fabiani B, Giani I, Menconi C. Micro-fragmented adipose tissue injection for the treatment of complex anal fistula: a pilot study accessing safety and feasibility. Tech Coloproctol. 2018;22:107&#x2013;113.</Citation></Reference><Reference><Citation>Norderval S, Lundby L, Hougaard H, Buntzen S, Weum S, de Weerd L. Efficacy of autologous fat graft injection in the treatment of anovaginal fistulas. Tech Coloproctol. 2018;22:45&#x2013;51.</Citation></Reference><Reference><Citation>Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2019;156:2208&#x2013;2216.e1.</Citation></Reference><Reference><Citation>Laureti S, Gionchetti P, Cappelli A, et al. Refractory complex Crohn&#x2019;s perianal fistulas: a role for autologous microfragmented adipose tissue injection. Inflamm Bowel Dis. 2020;26:321&#x2013;330.</Citation></Reference><Reference><Citation>Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum. 2011;54:1465&#x2013;1474.</Citation></Reference><Reference><Citation>Pu LLQ, Coleman SR, Cui X, Ferguson REH Jr, Vasconez HC. Autologous fat grafts harvested and refined by the Coleman technique: a comparative study. Plast Reconstr Surg. 2008;122:932&#x2013;937.</Citation></Reference><Reference><Citation>Zollino I, Campioni D, Sibilla MG, Tessari M, Malagoni AM, Zamboni P. A phase II randomized clinical trial for the treatment of recalcitrant chronic leg ulcers using centrifuged adipose tissue containing progenitor cells. Cytotherapy. 2019;21:200&#x2013;211.</Citation></Reference><Reference><Citation>Park SR, Kim JW, Jun HS, Roh JY, Lee HY, Hong IS. Stem cell secretome and its effect on cellular mechanisms relevant to wound healing. Mol Ther. 2018;26:606&#x2013;617.</Citation></Reference><Reference><Citation>Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy. 2016;18:13&#x2013;24.</Citation></Reference><Reference><Citation>Ceserani V, Ferri A, Berenzi A, et al. Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells. Vasc Cell. 2016;8:3.</Citation></Reference><Reference><Citation>Vezzani B, Shaw I, Lesme H, et al. Higher pericyte content and secretory activity of microfragmented human adipose tissue compared to enzymatically derived stromal vascular fraction. Stem Cells Transl Med. 2018;7:876&#x2013;886.</Citation></Reference><Reference><Citation>Ibatici A, Caviggioli F, Valeriano V, et al. Comparison of cell number, viability, phenotypic profile, clonogenic, and proliferative potential of adipose-derived stem cell populations between centrifuged and noncentrifuged fat. Aesthetic Plast Surg. 2014;38:985&#x2013;993.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33216494</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Abnormal Neuronal Response to Rectal and Anal Stimuli in Patients Treated for Distal Rectal Cancer With High-Dose Chemoradiotherapy Followed By Watchful Waiting.</ArticleTitle><Pagination><StartPage>1234</StartPage><EndPage>1241</EndPage><MedlinePgn>1234-1241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001610</ELocationID><Abstract><AbstractText Label="BACKGROUND">Watchful waiting in patients with rectal cancer with complete clinical response after chemoradiation therapy has gained increased popularity to avoid morbidity and mortality associated with surgery. Irradiation of the pelvis causes bowel dysfunction, but the effect on anorectal sensory function remains obscure in this patient category.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to characterize the sensory pathways of the gut-brain axis in patients with rectal cancer treated solely with chemoradiation therapy (nonconventional regime/dose) compared with healthy volunteers.</AbstractText><AbstractText Label="DESIGN">This is an explorative study.</AbstractText><AbstractText Label="SETTINGS">Sensory evaluation by rectal distension was performed and cortical evoked potentials were recorded during rapid balloon distensions of the rectum and anal canal. Latencies and amplitudes of cortical evoked potentials were compared, and the relative amplitude of 5 spectral bands from recorded cortical evoked potentials was used as an additional proxy of neuronal processing.</AbstractText><AbstractText Label="PATIENTS">Patients with rectal cancer solely with chemoradiation therapy (n = 13) a median of 3.2 years ago (range, 2.3-5.6 y) and healthy volunteers (n = 13) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Cortical evoked potentials were measured.</AbstractText><AbstractText Label="RESULTS">Patients had 35% lower rectal capacity at a maximum tolerable volume (p = 0.007). We found no differences in rectal cortical evoked potential latencies (p = 0.09) and amplitudes (p = 0.38) between groups. However, spectral analysis of rectal cortical evoked potentials showed a decrease in &#x3b8; (4-8 Hz) and an increase in &#x3b2; (12-32 Hz) band activity in patients (all p &lt; 0.001). Anal cortical potentials showed an increase in &#x3b1; (8-12 Hz) and &#x3b2; and a decrease in &#x3b3; (32-70 Hz) band activity (all p &lt; 0.001) in patients compared with healthy volunteers.</AbstractText><AbstractText Label="LIMITATIONS">This is an explorative study of limited size.</AbstractText><AbstractText Label="CONCLUSIONS">Chemoradiation therapy for distal rectal cancer causes abnormal cortical processing of both anal and rectal sensory input. Such central changes may play a role in symptomatic patients, especially when refractory to local treatments. See Video Abstract at http://links.lww.com/DCR/B270. RESPUESTA NEURONAL ANORMAL A EST&#xcd;MULOS RECTALES Y ANALES, EN PACIENTES TRATADOS POR C&#xc1;NCER RECTAL DISTAL, CON QUIMIORRADIOTERAPIA DE DOSIS ALTA, SEGUIDA DE ESPERA VIGILANTE: La espera vigilante en pacientes de c&#xe1;ncer rectal, con respuesta cl&#xed;nica completa despu&#xe9;s de la quimiorradiaci&#xf3;n, ha ganado una mayor popularidad en evitar la morbilidad y mortalidad asociadas con la cirug&#xed;a. La irradiaci&#xf3;n de la pelvis causa disfunci&#xf3;n intestinal, pero el efecto sobre la funci&#xf3;n sensorial ano-rectal sigue siendo no claro, en esta categor&#xed;a de pacientes.El objetivo de este estudio, fue caracterizar las v&#xed;as sensoriales del eje intestino-cerebro en pacientes con c&#xe1;ncer rectal, tratados &#xfa;nicamente con quimiorradiaci&#xf3;n (r&#xe9;gimen / dosis no convencional), en comparaci&#xf3;n con voluntarios sanos.Es un estudio exploratorio.Se realiz&#xf3; una evaluaci&#xf3;n sensorial por distensi&#xf3;n rectal y se registraron los potenciales evocados corticales, durante las distensiones r&#xe1;pidas con bal&#xf3;n en recto y canal anal. Se compararon las latencias y amplitudes de los potenciales evocados corticales, y la amplitud relativa de cinco bandas espectrales registradas, de potenciales evocados corticales, se usaron como proxy adicional del procesamiento neuronal.Pacientes de c&#xe1;ncer rectal, &#xfa;nicamente con terapia de quimiorradiaci&#xf3;n (n = 13) mediana de 3.2 a&#xf1;os (rango 2.3-5.6) y voluntarios sanos (n = 13).Potenciales evocados corticales.Pacientes tuvieron una capacidad rectal menor del 35%, al volumen m&#xe1;ximo tolerable (p = 0.007). No encontramos diferencias en las latencias potenciales evocadas corticales rectales (p = 0.09) y amplitudes (p = 0.38) entre los grupos. Sin embargo, el an&#xe1;lisis espectral de los potenciales evocados corticales rectales, mostr&#xf3; una disminuci&#xf3;n en theta (4-8 Hz) aumento en beta (12-32 Hz), y actividad en banda en pacientes (todos p &lt;0.001). Los potenciales evocados corticales anales mostraron un aumento en alfa (8-12 Hz) y beta, disminuci&#xf3;n en gamma (32-70 Hz), y actividad en banda (todos p &lt;0.001), en pacientes comparados a voluntarios sanos.Este es un estudio exploratorio de tama&#xf1;o limitado.La quimiorradiaci&#xf3;n para el c&#xe1;ncer rectal distal, ocasiona procesos corticales sensoriales anormales anales y rectales. Tales cambios centrales pueden desempe&#xf1;ar un papel en pacientes sintom&#xe1;ticos, especialmente cuando son refractarios a tratamientos locales. Consulte Video Resumen en http://links.lww.com/DCR/B270.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller Faaborg</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Vejle Hospital, Vejle, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mech-Sense, Department of Gastroenterology &amp; Hepatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krogh</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurogastroenterology Unit, Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gram</LastName><ForeName>Mikkel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mech-Sense, Department of Gastroenterology &amp; Hepatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundby</LastName><ForeName>Lilli</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohr Drewes</LastName><ForeName>Asbj&#xf8;rn</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mech-Sense, Department of Gastroenterology &amp; Hepatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurberg</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Cancer Society Centre for Research and Late Adverse Effects After Cancer in the Pelvic Organs, Aarhus and Aalborg University Hospitals, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1548R74NSZ</RegistryNumber><NameOfSubstance UI="D005641">Tegafur</NameOfSubstance></Chemical><Chemical><RegistryNumber>56HH86ZVCT</RegistryNumber><NameOfSubstance UI="D014498">Uracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005073" MajorTopicYN="N">Evoked Potentials, Somatosensory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008365" MajorTopicYN="N">Manometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005641" MajorTopicYN="N">Tegafur</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014498" MajorTopicYN="N">Uracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017833" MajorTopicYN="N">Visceral Afferents</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="Y">Watchful Waiting</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>15</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33216494</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001610</ArticleId><ArticleId IdType="pii">00003453-202009000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg. 1982;69:613&#x2013;616.</Citation></Reference><Reference><Citation>Hoffe SE, Shridhar R, Biagioli MC. Radiation therapy for rectal cancer: current status and future directions. Cancer Control. 2010;17:25&#x2013;34.</Citation></Reference><Reference><Citation>Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8 Suppl 3:21&#x2013;24.</Citation></Reference><Reference><Citation>Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554&#x2013;1562.</Citation></Reference><Reference><Citation>Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770&#x2013;1776.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer. Acta Oncol. 2008;47:994&#x2013;1003.</Citation></Reference><Reference><Citation>Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922&#x2013;928.</Citation></Reference><Reference><Citation>Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL. Anterior resection syndrome. Lancet Oncol. 2012;13:e403&#x2013;e408.</Citation></Reference><Reference><Citation>Appelt AL, Pl&#xf8;en J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919&#x2013;927.</Citation></Reference><Reference><Citation>Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77&#x2013;97.</Citation></Reference><Reference><Citation>Ryhammer AM, Laurberg S, Hermann AP. Test-retest repeatability of anorectal physiology tests in healthy volunteers. Dis Colon Rectum. 1997;40:287&#x2013;292.</Citation></Reference><Reference><Citation>Petersen P, Gao C, Arendt-Nielsen L, Gregersen H, Drewes AM. Pain intensity and biomechanical responses during ramp-controlled distension of the human rectum. Dig Dis Sci. 2003;48:1310&#x2013;1316.</Citation></Reference><Reference><Citation>Nissen TD, Brock C, Graversen C, et al. Translational aspects of rectal evoked potentials: a comparative study in rats and humans. Am J Physiol Gastrointest Liver Physiol. 2013;305:G119&#x2013;G128.</Citation></Reference><Reference><Citation>Haas S, Brock C, Krogh K, et al. Cortical evoked potentials in response to rapid balloon distension of the rectum and anal canal. Neurogastroenterol Motil. 2014;26:862&#x2013;873.</Citation></Reference><Reference><Citation>Tonner PH, Bein B. Classic electroencephalographic parameters: median frequency, spectral edge frequency etc. Best Pract Res Clin Anaesthesiol. 2006;20:147&#x2013;159.</Citation></Reference><Reference><Citation>Gram M, Graversen C, Nielsen AK, et al. A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials. Br J Clin Pharmacol. 2013;76:951&#x2013;963.</Citation></Reference><Reference><Citation>Haas S, Brock C, Krogh K, et al. Abnormal neuronal response to rectal and anal stimuli in patients with idiopathic fecal incontinence. Neurogastroenterol Motil. 2015;27:954&#x2013;962.</Citation></Reference><Reference><Citation>Haas S, Brock C, Krogh K, et al. Does sacral nerve stimulation improve continence through enhanced sensitivity of the anal canal? A pilot study. Dis Colon Rectum. 2016;59:1039&#x2013;1046.</Citation></Reference><Reference><Citation>Haas S, Faaborg P, Gram M, et al. Abnormal neuronal response to rectal and anal stimuli in patients treated with primary radiotherapy for anal cancer. Radiother Oncol. 2018;128:369&#x2013;374.</Citation></Reference><Reference><Citation>Klem GH, L&#xfc;ders HO, Jasper HH, Elger C. The ten-twenty electrode system of the International Federation: The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999;52:3&#x2013;6.</Citation></Reference><Reference><Citation>Bregendahl S, Emmertsen KJ, Lindegaard JC, Laurberg S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis. 2015;17:26&#x2013;37.</Citation></Reference><Reference><Citation>Romaniszyn M, Richter P, Walega P, Kenig J, Nowak M, Nowak W. Low-anterior-resection syndrome: how does neoadjuvant radiotherapy and low resection of the rectum influence the function of anal sphincters in patients with rectal cancer? Preliminary results of a functional assessment study. Pol Przegl Chir. 2012;84:177&#x2013;183.</Citation></Reference><Reference><Citation>Krol R, Hopman WP, Smeenk RJ, Van Lin EN. Increased rectal wall stiffness after prostate radiotherapy: relation with fecal urgency. Neurogastroenterol Motil. 2012;24:339&#x2013;e166.</Citation></Reference><Reference><Citation>Pradat PF, Delanian S. Late radiation injury to peripheral nerves. Handb Clin Neurol. 2013;115:743&#x2013;758.</Citation></Reference><Reference><Citation>Lange MM, van de Velde CJ. The role of radiotherapy in the causation of poor function after rectal cancer treatment. Colorectal Dis. 2013;15:120&#x2013;121.</Citation></Reference><Reference><Citation>Lundby L, Krogh K, Jensen VJ, et al. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum. 2005;48:1343&#x2013;1349.</Citation></Reference><Reference><Citation>Sengupta JN, Gebhart GF. Characterization of mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat. J Neurophysiol. 1994;71:2046&#x2013;2060.</Citation></Reference><Reference><Citation>Rink AD, Kneist W, Radinski I, Guinot-Barona A, Lang H, Vestweber KH. Differences in ano-neorectal physiology of ileoanal and coloanal reconstructions for restorative proctectomy. Colorectal Dis. 2010;12:342&#x2013;350.</Citation></Reference><Reference><Citation>Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22:216&#x2013;241.</Citation></Reference><Reference><Citation>Bregendahl S, Emmertsen KJ, Fassov J, et al. Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol. 2013;108:331&#x2013;336.</Citation></Reference><Reference><Citation>Kirmizi-Alsan E, Bayraktaroglu Z, Gurvit H, Keskin YH, Emre M, Demiralp T. Comparative analysis of event-related potentials during Go/NoGo and CPT: decomposition of electrophysiological markers of response inhibition and sustained attention. Brain Res. 2006;1104:114&#x2013;128.</Citation></Reference><Reference><Citation>Baker SN. Oscillatory interactions between sensorimotor cortex and the periphery. Curr Opin Neurobiol. 2007;17:649&#x2013;655.</Citation></Reference><Reference><Citation>Banahan M, Peirce C, Buffini M, O&#x2019;Herlihy C, O&#x2019;Connell PR, Jones JF. Atrophy of the sphincters of continence in an experimental model. Colorectal Dis. 2010;12(7 Online):e153&#x2013;e157.</Citation></Reference><Reference><Citation>Griffin KM, O&#x2019;Herlihy C, O&#x2019;Connell PR, Jones JF. Combined ischemic and neuropathic insult to the anal canal in an animal model of obstetric-related trauma. Dis Colon Rectum. 2012;55:32&#x2013;41.</Citation></Reference><Reference><Citation>Pierce LM, Rankin MR, Foster RT, et al. Distribution and immunohistochemical characterization of primary afferent neurons innervating the levator ani muscle of the female squirrel monkey. Am J Obstet Gynecol. 2006;195:987&#x2013;996.</Citation></Reference><Reference><Citation>Huang Y, Koh CE. Sacral nerve stimulation for bowel dysfunction following low anterior resection: a systematic review and meta-analysis. Colorectal Dis. 2019;21:1240&#x2013;1248.</Citation></Reference><Reference><Citation>Ramage L, Qiu S, Kontovounisios C, Tekkis P, Rasheed S, Tan E. A systematic review of sacral nerve stimulation for low anterior resection syndrome. Colorectal Dis. 2015;17:762&#x2013;771.</Citation></Reference><Reference><Citation>Evers J, Devane L, Carrington EV, et al. Reversal of sensory deficit through sacral neuromodulation in an animal model of fecal incontinence. Neurogastroenterol Motil. 2016;28:665&#x2013;673.</Citation></Reference><Reference><Citation>Griffin KM, Pickering M, O&#x2019;Herlihy C, O&#x2019;Connell PR, Jones JF. Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model. Br J Surg. 2011;98:1160&#x2013;1169.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32472777</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Ileorectal Anastomosis Versus IPAA for the Surgical Treatment of Ulcerative Colitis: A Markov Decision Analysis.</ArticleTitle><Pagination><StartPage>1276</StartPage><EndPage>1284</EndPage><MedlinePgn>1276-1284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001686</ELocationID><Abstract><AbstractText Label="BACKGROUND">Ileorectal anastomosis in patients with ulcerative colitis results in decreased postoperative morbidity and better functional outcome but leads to increased risk for rectal cancer compared with IPAA.</AbstractText><AbstractText Label="OBJECTIVE">This study aims to compare ileorectal anastomosis with IPAA in ulcerative colitis by using a decision model.</AbstractText><AbstractText Label="DESIGN">A Markov simulation model was designed to simulate clinical events of ileorectal anastomosis and IPAA over a time horizon of 40 years with time cycles of 1 year. All probabilities and utilities were derived from observational studies, identified after a systematic literature search using MEDLINE. Primary outcomes were life-years and quality-adjusted life-years. Deterministic and probabilistic sensitivity analyses were performed.</AbstractText><AbstractText Label="SETTINGS">A decision model using Markov simulation was designed.</AbstractText><AbstractText Label="PATIENTS">The base case was a 35-year-old patient with ulcerative colitis and a relatively preserved rectum.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES">The primary outcome measures were (quality-adjusted) life-years.</AbstractText><AbstractText Label="RESULTS">The model resulted in lower life-years (36.22 vs 37.02) and higher quality-adjusted life-years (33.42 vs 31.57) for ileorectal anastomosis. This was confirmed after probabilistic sensitivity analysis. The model was sensitive to the utility of ileorectal anastomosis, IPAA, and end-ileostomy. A higher proportion of patients with ileorectal anastomosis will develop rectal cancer (7.6% vs 3.2%) and 43.5% of all patients with ileorectal anastomosis will end with an ileostomy as opposed to 23.0% of all patients with IPAA.</AbstractText><AbstractText Label="LIMITATIONS">The study was limited by characteristics inherent to modeling studies, including assumptions necessary to build the model, data input based on best available but often limited evidence, and unavoidable extra- and interpolation of data.</AbstractText><AbstractText Label="CONCLUSIONS">Ileorectal anastomosis was the preferred treatment option when quality-adjusted life-years were the outcome, with higher life-years for IPAA. This model highlights that both surgical strategies are useful in patients who have ulcerative colitis with a relatively spared rectum. See Video Abstract at http://links.lww.com/DCR/B249. ANASTOMOSIS ILEORRECTAL VERSUS ANASTOMOSIS ANAL CON RESERVORIO ILEAL EN EL TRATAMIENTO QUIR&#xda;RGICO DE LA COLITIS ULCEROSA: AN&#xc1;LISIS DE DECISI&#xd3;N DE MARKOV: Las anastomosis ileorrectales en pacientes con colitis ulcerosa se encuentran asociadas con la disminuci&#xf3;n de la morbilidad postoperatoria y un mejor resultado funcional, pero conducen a un mayor riesgo de c&#xe1;ncer de recto cuando se las compara con casos de confecci&#xf3;n de un reservorio &#xed;leo-anal.Comparar las anastomosis ileorrectales con la anastomosis de un reservorio &#xed;leo-anal en casos de colitis ulcerosa, utilizando un modelo de procesos de decisi&#xf3;n.Se dise&#xf1;&#xf3; un modelo de proceso de Markov para simular eventos cl&#xed;nicos en casos de anastomosis ileorrectales y anastomosis de reservorios &#xed;leo-anales en un horizonte temporal de 40 a&#xf1;os comprendiendo ciclos temporales de 1 a&#xf1;o. Todas las probabilidades y utilidades se derivaron de estudios observacionales, identificados despu&#xe9;s de una b&#xfa;squeda sistem&#xe1;tica de literatura usando MEDLINE. Los resultados primarios fueron a&#xf1;os de vida y los a&#xf1;os ajustados a la calidad de vida. Se realizaron los an&#xe1;lisis de sensibilidad determinada y de probabil&#xed;stica.Se dise&#xf1;&#xf3; un modelo de decisi&#xf3;n utilizando el proceso de simulaci&#xf3;n de Markov.El caso base fue el de un paciente de 35 a&#xf1;os con colitis ulcerosa y con un recto relativamente sano.El resultado principal fu&#xe9; la medida de los a&#xf1;os de vida (con ajuste en la calidad de vida).El modelo result&#xf3; en menos a&#xf1;os de vida (36.22 frente a 37.02) y a&#xf1;os de vida de menor calidad (33.42 frente a 31.57) para los casos de anastomosis ileorrectales. Esto se confirm&#xf3; despu&#xe9;s del an&#xe1;lisis de sensibilidad probabil&#xed;stica. El modelo era sensible a la utilidad de la anastomosis ileorrectal, la anastomosis del reservorio &#xed;leo-anal y la ileostom&#xed;a terminal. Una mayor proporci&#xf3;n de pacientes con anastomosis ileorectales desarrollar&#xe1;n c&#xe1;ncer de recto (7,6% frente a 3,2%) y el 43,5% de todos los pacientes con anastomosis ileorrectales terminar&#xe1;n con una ileostom&#xed;a en comparaci&#xf3;n con el 23,0% de todos los pacientes con un reservorio &#xed;leo-anal.El analisis estuvo limitado por las caracter&#xed;sticas inherentes a los estudios de modelado, incluidas las suposiciones necesarias para construir el modelo, la entrada de datos basada en la mejor evidencia disponible pero a menudo limitada y la extrapolaci&#xf3;n e interpolaci&#xf3;n inevitable de datos.Las anastomosis ileorrectales fueron la opci&#xf3;n de tratamiento preferida cuando el resultado fue ajustado en a&#xf1;os con calidad de vida, con a&#xf1;os de vida m&#xe1;s larga para la anastomosis de reservorios &#xed;leo-anales. Este modelo destaca que ambas estrategias quir&#xfa;rgicas son &#xfa;tiles en pacientes con colitis ulcerosa con rectos relativamente sanos. Consulte Video Resumen en http://links.lww.com/DCR/B249.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Buck van Overstraeten</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zane Cohen Centre for Digestive Diseases, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brar</LastName><ForeName>Mantaj S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zane Cohen Centre for Digestive Diseases, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorasani</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dossa</LastName><ForeName>Fahima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myrelid</LastName><ForeName>P&#xe4;r</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Surgery, Link&#xf6;ping University Hospital, and Division of Surgery, Department of Experimental Medicine, Faculty of Health Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007081" MajorTopicYN="N">Ileostomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007082" MajorTopicYN="N">Ileum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008390" MajorTopicYN="N">Markov Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019449" MajorTopicYN="N">Pouchitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011349" MajorTopicYN="N">Proctitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016737" MajorTopicYN="N">Proctocolectomy, Restorative</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32472777</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001686</ArticleId><ArticleId IdType="pii">00003453-202009000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Myrelid P, &#xd8;resland T. A reappraisal of the ileo-rectal anastomosis in ulcerative colitis. J Crohns Colitis. 2015;9:433&#x2013;438.</Citation></Reference><Reference><Citation>Andersson P, Norblad R, S&#xf6;derholm JD, Myrelid P. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis&#x2013;a single institution experience. J Crohns Colitis. 2014;8:582&#x2013;589.</Citation></Reference><Reference><Citation>Nordenvall C, Ol&#xe9;n O, Johan Nilsson P, et al. Restorative surgery in patients with primary sclerosing cholangitis and ulcerative colitis following a colectomy. Inflamm Bowel Dis. 2018;24:624&#x2013;632.</Citation></Reference><Reference><Citation>da Luz Moreira A, Lavery IC. Ileorectal anastomosis and proctocolectomy with end ileostomy for ulcerative colitis. Clin Colon Rectal Surg. 2010;23:269&#x2013;273.</Citation></Reference><Reference><Citation>da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010;97:65&#x2013;69.</Citation></Reference><Reference><Citation>Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004;136:795&#x2013;803.</Citation></Reference><Reference><Citation>Bartels SA, D&#x2019;Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg. 2012;256:1045&#x2013;1048.</Citation></Reference><Reference><Citation>Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg. 2013;258:275&#x2013;282.</Citation></Reference><Reference><Citation>Baker WN, Glass RE, Ritchie JK, Aylett SO. Cancer of the rectum following colectomy and ileorectal anastomosis for ulcerative colitis. Br J Surg. 1978;65:862&#x2013;868.</Citation></Reference><Reference><Citation>Abdalla M, Landerholm K, Andersson P, Andersson RE, Myrelid P. Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study. Clin Gastroenterol Hepatol. 2017;15:1055&#x2013;1060.e2.</Citation></Reference><Reference><Citation>Uzzan M, Cosnes J, Amiot A, et al. Long-term follow-up after ileorectal anastomosis for ulcerative colitis: a GETAID/GETAID Chirurgie Multicenter retrospective cohort of 343 patients. Ann Surg. 2017;266:1029&#x2013;1034.</Citation></Reference><Reference><Citation>Sonnenberg A, Gavin MW. Timing of surgery for enterovesical fistula in Crohn&#x2019;s disease: decision analysis using a time-dependent compartment model. Inflamm Bowel Dis. 2000;6:280&#x2013;285.</Citation></Reference><Reference><Citation>Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587&#x2013;611.</Citation></Reference><Reference><Citation>Uzzan M, Kirchgesner J, Oubaya N, et al. Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis. J Crohns Colitis. 2017;11:930&#x2013;935.</Citation></Reference><Reference><Citation>Landerholm K, Abdalla M, Myrelid P, Andersson RE. Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study. Scand J Gastroenterol. 2017;52:531&#x2013;535.</Citation></Reference><Reference><Citation>Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology. 2010;139:806&#x2013;812.</Citation></Reference><Reference><Citation>Benitez Majano S, Di Girolamo C, Rachet B, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol. 2019;20:74&#x2013;87.</Citation></Reference><Reference><Citation>Dossa F, Morris AM, Wilson AR, Baxter NN. Life after surgery: surgeon assessments of quality of life among patients with familial adenomatous polyposis. Dis Colon Rectum. 2018;61:1217&#x2013;1222.</Citation></Reference><Reference><Citation>Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res. 2010;19:391&#x2013;400.</Citation></Reference><Reference><Citation>Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 4&#x2013;analyzing the model and interpreting the results. Med Decis Making. 1997;17:142&#x2013;151.</Citation></Reference><Reference><Citation>Canada Stats. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011401. Accessed December 12, 2018.</Citation></Reference><Reference><Citation>Wu XR, Kiran RP, Remzi FH, Katz S, Mukewar S, Shen B. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. J Crohns Colitis. 2013;7:e419&#x2013;e426.</Citation></Reference><Reference><Citation>Baek SJ, Lightner AL, Boostrom SY, et al. Functional outcomes following laparoscopic ileal pouch-anal anastomosis in patients with chronic ulcerative colitis: long-term follow-up of a case-matched study. J Gastrointest Surg. 2017;21:1304&#x2013;1308.</Citation></Reference><Reference><Citation>Farouk R, Pemberton JH, Wolff BG, Dozois RR, Browning S, Larson D. Functional outcomes after ileal pouch-anal anastomosis for chronic ulcerative colitis. Ann Surg. 2000;231:919&#x2013;926.</Citation></Reference><Reference><Citation>Leowardi C, Hinz U, Tariverdian M, et al. Long-term outcome 10 years or more after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Langenbecks Arch Surg. 2010;395:49&#x2013;56.</Citation></Reference><Reference><Citation>Pastore RL, Wolff BG, Hodge D. Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease. Dis Colon Rectum. 1997;40:1455&#x2013;1464.</Citation></Reference><Reference><Citation>Olsen K&#xd8;, Juul S, B&#xfc;low S, et al. Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg. 2003;90:227&#x2013;231.</Citation></Reference><Reference><Citation>Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol. 2016;28:383&#x2013;390.</Citation></Reference><Reference><Citation>Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842&#x2013;1852.</Citation></Reference><Reference><Citation>Guerra I, Bujanda L, Castro J, et al.; Spanish GETECCU group (ENEIDA Project). (ENEIDA Project). Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicenter retrospective cohort study. J Crohn&#x2019;s Colitis. 2019;13:1492&#x2013;1500.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31318769</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Diverticular Colovaginal Fistulas: What Factors Contribute to Successful Surgical Management?</ArticleTitle><Pagination><StartPage>1079</StartPage><EndPage>1084</EndPage><MedlinePgn>1079-1084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001445</ELocationID><Abstract><AbstractText Label="BACKGROUND">Diverticular disease is the leading cause of colovaginal fistulas. Surgery is challenging given the inflammatory process that makes dissection difficult. To date, studies are small and include fistula secondary to multiple etiologies.</AbstractText><AbstractText Label="OBJECTIVE">The objectives of this study were to examine surgical outcomes of diverticular colovaginal fistulas and to identify variables associated with successful closure.</AbstractText><AbstractText Label="DESIGN">This was a retrospective study of a prospectively maintained clinical database.</AbstractText><AbstractText Label="SETTINGS">The study was conducted at a single tertiary referral center.</AbstractText><AbstractText Label="PATIENTS">Women with diverticular colovaginal fistulas, who underwent surgical repair with intent to close the fistula, were included.</AbstractText><AbstractText Label="INTERVENTIONS">Repair of colovaginal fistula through minimally invasive or open techniques was involved.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Successful closure of fistula, defined as resolution of symptoms and no stoma, was measured.</AbstractText><AbstractText Label="RESULTS">Fifty-two patients underwent surgical treatment of diverticular colovaginal fistula, 23 (44%) of whom underwent a minimally invasive approach (conversion rate of 22%). Ostomy construction and omental pedicle flaps were used in 28 (54%) and 38 patients (73%). Surgery was successful in 47 patients (90%). Accounting for secondary operations, ultimate success and failure rates were 49 (94.0%) and 3 (5.7%). There was no difference in postoperative morbidity between the 2 groups (5 patients with Clavien-Dindo III/IV complications in the success group versus 2 patients in the failure group; 10.6% vs 40.0%; p = 0.44). Failure to achieve fistula closure was not associated with perioperative variables, age, BMI, diabetes mellitus, ASA grade, steroid use, previous abdominal surgery or hysterectomy, use of omentoplasty, or ostomy. Patients who failed were more likely to be smokers (60.0% vs 12.8%; p = 0.03).</AbstractText><AbstractText Label="LIMITATIONS">Limitations include the retrospective design and lack of power.</AbstractText><AbstractText Label="CONCLUSIONS">Surgery is effective in achieving successful closure of diverticular colovaginal fistula. Smokers should be encouraged to stop before embarking on an elective repair. Although the use of fecal diversion and omental pedicle flaps did not correlate with success, they should be used when clinically appropriate. See Video Abstract at http://links.lww.com/DCR/A983. F&#xcd;STULAS COLOVAGINALES DIVERTICULARES &#xbf;QU&#xc9; FACTORES CONTRIBUYEN AL &#xc9;XITO DEL TRATAMIENTO QUIR&#xda;RGICO?: La enfermedad diverticular es la causa principal de f&#xed;stulas colovaginales. La cirug&#xed;a es un reto dado el proceso inflamatorio que dificulta la disecci&#xf3;n. Hasta la fecha, los estudios son peque&#xf1;os e incluyen f&#xed;stulas secundarias a m&#xfa;ltiples etiolog&#xed;as.</AbstractText><AbstractText Label="OBJETIVO">1) Examinar los resultados quir&#xfa;rgicos de las f&#xed;stulas colovaginales diverticulares; 2) Identificar variables asociadas a un cierre exitoso. DISE&#xd1;O:: Estudio retrospectivo de una base de datos cl&#xed;nicos prospectivamente mantenida. CONFIGURACI&#xd3;N:: Centro de referencia superior.</AbstractText><AbstractText Label="PACIENTES">Mujeres con f&#xed;stulas colovaginales diverticulares, que se sometieron a una reparaci&#xf3;n quir&#xfa;rgica con la intenci&#xf3;n de cerrar la f&#xed;stula.</AbstractText><AbstractText Label="INTERVENCIONES">Reparaci&#xf3;n de la f&#xed;stula colovaginal mediante t&#xe9;cnicas m&#xed;nimamente invasivas o abiertas.</AbstractText><AbstractText Label="MEDIDAS DE RESULTADOS PRINCIPALES">Cierre exitoso de la f&#xed;stula definida como resoluci&#xf3;n de los s&#xed;ntomas y sin estoma.</AbstractText><AbstractText Label="RESULTADOS">Cincuenta y dos pacientes se sometieron a tratamiento quir&#xfa;rgico de la f&#xed;stula colovaginal diverticular, 23 (44%) de los cuales se sometieron a un acceso m&#xed;nimamente invasivo (tasa de conversi&#xf3;n del 22%). La construcci&#xf3;n de la ostom&#xed;a y los ped&#xed;culos omentales se utilizaron en 28 (54%) y 38 pacientes (73%), respectivamente. La cirug&#xed;a fue exitosa en 47 pacientes (90%). Tomando en cuenta las operaciones secundarias, las tasas finales de &#xe9;xito y fracaso fueron 49 (94.0%) y 3 (5.7%). No hubo diferencias en la morbilidad postoperatoria entre los dos grupos (5 pacientes con complicaciones de Clavien-Dindo III / IV en el grupo de &#xe9;xito versus a 2 pacientes en el grupo de fracaso, 10.6% versus a 40.0%; p = 0.44). El fracaso para lograr el cierre de la f&#xed;stula no se asoci&#xf3; con variables perioperatorios, edad, IMC, diabetes, grado ASA, uso de esteroides, cirug&#xed;a abdominal previa o histerectom&#xed;a, uso de omentoplastia u ostom&#xed;a. Los pacientes que fracasaron eran m&#xe1;s propensos a ser fumadores (60.0% versus a 12.8%; p = 0.03).</AbstractText><AbstractText Label="LIMITACIONES">Las limitaciones incluyen el dise&#xf1;o retrospectivo y la falta de poder.</AbstractText><AbstractText Label="CONCLUSIONES">La cirug&#xed;a es efectiva para lograr el cierre exitoso de la f&#xed;stula colovaginal diverticular. Se debe aconsejar a los fumadores a parar de fumar antes de embarcarse en una reparaci&#xf3;n electiva. Mientras el uso de desviaci&#xf3;n fecal y ped&#xed;culos omentales no se correlacion&#xf3; con el &#xe9;xito, deber&#xed;an utilizarse cuando sea cl&#xed;nicamente apropiado. Consulte el Video del Resumen en http://links.lww.com/DCR/A983.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeLeon</LastName><ForeName>Michelle F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapci</LastName><ForeName>Ipek</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akeel</LastName><ForeName>Nouf Y</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocchi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hull</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004241" MajorTopicYN="N">Diverticulum, Colon</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007412" MajorTopicYN="N">Intestinal Fistula</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014624" MajorTopicYN="N">Vaginal Fistula</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31318769</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001445</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>